Advocate. Wonk. Communicator. Managing Director @OncologyCOA. Tweets are personal views & RTs/likes are not endorsements (but I would be flattered if you cared)
“The U.S. pharmacy benefits market has been built to obfuscate price information and blind decision-makers to how drug costs are set, calculated, and passed down to health plans and employees.” @SmithRx_PBM
https://t.co/iwcV0sbVja
CVS store-brand drugs are a few dollars cheaper and consumers could assume they're the same as the big, name brand ones. Mold, bacteria and barefoot factory workers say otherwise.
Read my latest investigation: https://t.co/M4NDVktqji
In 1991 my father nearly died of sepsis
He was in an ICU with ZERO white blood cells after treatment for cancer
His oncologist came in with a new medicine (literally approved that week by the FDA!) to stimulate his bone marrow
33 years later insurers are still fighting its use
Can’t wait for this session at #COA2024 - I’ll be sharing details about my post fellowship plans including a role supporting VBC efforts @TNOncology! Hope to inspire other fellows and showcase the personalized leadership opportunities available at a community oncology practice!
Pretty interesting yet simple analysis that Cigna is not an insurance company. No surprise that is a big reason it acquired the #PBM Express Scripts.
https://t.co/JpmhBUiZMl
LOSER: Family medicine.
Interest in FM continues to decline.
This year, the average FM program received just 605 applications. That’s down from 865 in 2021 and 1023 in 2018. 😳
FM had more SOAP positions than any other specialty last year - and likely will this year, too.
But the underlying reason for shortages is the same in Europe as in the United States... Prices have been driven down so low that generic drugmakers either exit the market or they don’t update their facilities, which can result in production interruptions
https://t.co/vcuuledcAF
Today, COA Vice President @dapattmd testified in front of the @HouseCommerce committee on improving patient access to care, including the danger of continued Medicare fee schedule cuts, staffing shortages, and more. Thank you Dr. Patt! @TexasOncology
“The contracts that pharmacy benefit managers have with pharmacies are take-it-or-leave-it contracts,” Arnold said. “There is rarely much negotiation, if any. It barely covers the cost of the medications.”
from @seattletimes
https://t.co/KztEEty2gW
Last week, COA VP @dapattmd testified in front of Congress on ways to improve Medicare recipients' access to care - from @cspan
https://t.co/OlUXEXSaks
Had an amazing night at the @YorkCancer#RaisingHopeGala celebrating an our fearless leader in cancer advocacy, @TedOkonCOA.
What a beautiful gathering and fun time, all for such a good cause. Huge kudos to Dr. @_vacirca for what you have built and throwing a great party!
BREAKING NEWS: #Medicare seniors' premiums & deductibles will increase by 6% fueled by @CMSGov overpaying #340B hospitals by 50%. Even CMS admits in its release that 340B "remedy" fuels the increase in part. I am truly speechless!!! @BrooksLaSureCMS@SecBecerra
"[The main symptoms of the new Omicron strain EG.5.1] are a sore throat, a runny nose, a blocked nose, sneezing, a cough without phlegm, a headache, a cough with phlegm, a hoarse voice, muscle aches and pains and an altered sense of smell..
However, shortness of breath, a loss of smell and a fever are no longer the main symptoms."
Fever is no longer the main symptom..
https://t.co/GDY712OpIi
Resistance from the University of Minnesota, whose main teaching hospital in Minneapolis is part of Fairview, and an investigation by Minnesota's attorney general, helped doom the deal. https://t.co/Bdb1e8dJ3L
You can take pretty much every student activist cancel culture free speech panic story from the last few years and pile then on top of one another and, even together, they’re not as egregious or shocking as this one story:
Research and patient experience shows that hospital consolidation is bad for patients. Less choice. Worse care. Higher prices. What to do about it is unclear. My thoughts on this conundrum. @NYTimesOpEd@KFFHealthNews https://t.co/DFLtxlLEjA